Clinical trial · Observational
UWCCC Molecular Tumor Board Registry
UWCCC Precision Medicine Molecular Tumor Board Registry
NCT03023202CI-TRIAL-00107880recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Neoplasms | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Solid Neoplasm | Solid Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PMMTB (Precision Medicine Molecular Tumor Board) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- PMMTB
- description
- This study of the PMMTB will include all patients \>= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. All standard of care functions will be performed by standard procedures.
- interventionNames
- Other: PMMTB (Precision Medicine Molecular Tumor Board)
Primary outcomes (2)
- measure
- Frequency of acceptance of molecular tumor board recommendations
- timeFrame
- Up to 5 years
- description
- How often the molecular tumor board's recommendations are accepted
- measure
- Benefit from PMMTB recommended treatment
- timeFrame
- Up to 5 years
- description
- Whether patients benefit from PMMTB recommended treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically suspected or histologically confirmed solid or hematological malignancy * Undergoing genetic testing of tumor * Ability to understand written informed consent document * Willingness to sign written informed consent document Exclusion Criteria: * Pediatric patients (age\<18 years) will be excluded due to a lack of expertise on the molecular tumor committee
References
Publications (0)
Data not yet available
No reference posted for this study.